Phospho-GRIA1 (Ser849) Antibody

What is GRIA1 and what role does phosphorylation at Ser849 play in its function?

GRIA1 (Glutamate Receptor Ionotropic AMPA type 1, also known as GluR1 or GluA1) is a subunit of AMPA receptors, which are essential for excitatory neurotransmission in the central nervous system. GRIA1 is a ~100 kDa, 4-transmembrane protein that belongs to the glutamate-gated ion channel family .

Phosphorylation of GRIA1 at Ser849 (which corresponds to Ser845 in some species numbering) regulates the trafficking and functional properties of AMPA receptors, significantly impacting synaptic strength and plasticity . Specifically:

• Phosphorylation at Ser849 helps ensure membrane localization of the subunit

• Changes in phosphorylation status at this site are associated with long-term potentiation (LTP) and long-term depression (LTD)

• This phosphorylation site is regulated by Protein Kinase A (PKA) and other kinases

Research indicates that understanding the phosphorylation status of GRIA1 is crucial for investigating mechanisms of synaptic transmission and the pathophysiology of neurological disorders including Alzheimer's disease, epilepsy, and schizophrenia .

How do Phospho-GRIA1 (Ser849) antibodies differ from other GRIA1 antibodies?

Phospho-GRIA1 (Ser849) antibodies are specifically designed to recognize GRIA1 only when it is phosphorylated at the Serine 849 residue, unlike general GRIA1 antibodies that detect the protein regardless of its phosphorylation state . Key differences include:

• Specificity: These antibodies are generated using phospho-specific peptides corresponding to residues surrounding Ser849 (typically a sequence like Q-Q-S(p)-I-N)

• Purification method: They undergo specialized purification, typically via affinity chromatography using epitope-specific phosphopeptides, with non-phospho specific antibodies removed through chromatography using non-phosphopeptide

• Validation: The phosphospecificity is demonstrated through treatments with phosphatases (like lambda Phosphatase) to show elimination of immunolabeling

• Application range: While general GRIA1 antibodies may work in multiple applications, phospho-specific antibodies are typically validated for specific applications like Western blot and ELISA

This specificity makes phospho-GRIA1 antibodies invaluable for studying the dynamic regulation of AMPA receptor function through post-translational modifications.

What are the validated applications for Phospho-GRIA1 (Ser849) antibodies?

Phospho-GRIA1 (Ser849) antibodies have been validated for several research applications, with varying levels of optimization required:

Western Blotting (WB): The most common and thoroughly validated application

• Typical dilution ranges: 1:500 to 1:2000

• Expected molecular weight: ~100 kDa

• Control samples: Mouse or rat brain lysates are recommended positive controls

• Validation method: Comparison with phosphatase-treated samples

Enzyme-Linked Immunosorbent Assay (ELISA)

• Used for quantitative measurement of phosphorylated GRIA1 levels

• Offers higher throughput than Western blotting

Immunohistochemistry (IHC)

• Typically used at dilutions around 1:1000

• Allows visualization of phosphorylated GRIA1 distribution in tissue sections

For all applications, researchers should perform optimization with appropriate controls, including phosphatase treatment to confirm specificity for the phosphorylated form of the protein.

What species reactivity can be expected from commercial Phospho-GRIA1 (Ser849) antibodies?

Commercial Phospho-GRIA1 (Ser849) antibodies typically demonstrate reactivity across multiple mammalian species due to the high conservation of the phosphorylation site and surrounding amino acid sequence. Based on product specifications, the following reactivity pattern is commonly observed:

When selecting an antibody for cross-species applications, researchers should:

• Review the immunogen sequence and confirm its conservation across target species

• Request validation data specific to their species of interest

• Consider performing pilot experiments with appropriate positive controls

How can one determine the proportion of GRIA1 subunits phosphorylated at Ser849 in neuronal samples?

Determining the precise proportion of GRIA1 subunits phosphorylated at Ser849 requires specialized quantitative approaches. Based on methodologies used for similar phosphorylation sites (like Ser845 and T840), the following approaches are recommended:

Immunodepletion Assay :

• Prepare neuronal homogenates under conditions that preserve phosphorylation (phosphatase inhibitors)

• Split samples into two portions

• Immunoprecipitate one portion with phospho-specific antibodies to remove phosphorylated subunits

• Compare total GRIA1 levels in the unbound fraction with the input sample using Western blot

• Calculate the proportion of phosphorylated receptors based on the depletion level

A study examining similar phosphorylation sites (S845 and T840) found that approximately 50% of GluA1 subunits are basally phosphorylated at T840, while few subunits were phosphorylated at S845 in hippocampal neurons . This methodology would be applicable to Ser849 phosphorylation analysis.

Phosphatase Treatment Comparison :

• Prepare paired samples with and without lambda phosphatase treatment

• Quantify the reduction in signal using phospho-specific antibodies

• Use total GRIA1 antibodies to normalize for protein loading

Phospho/Total Ratio Determination:

• Perform parallel Western blots with phospho-specific and total GRIA1 antibodies

• Use purified phosphorylated and non-phosphorylated peptides to create standard curves

• Calculate absolute quantities based on standard curves

For enhanced accuracy, consider the effect of detergents and sample preparation on epitope accessibility and always include appropriate controls.

How do different phosphorylation sites on GRIA1 interact with each other, and what methodologies can distinguish these relationships?

GRIA1 contains multiple phosphorylation sites (including Ser831, Ser845, Ser818, Thr840, and Ser849) that can be phosphorylated by different kinases and potentially interact with each other. Understanding these interactions requires sophisticated methodological approaches:

Sequential Immunoprecipitation :

• First immunoprecipitate with antibodies against one phosphorylation site

• Then probe the immunoprecipitate with antibodies against other phosphorylation sites

• Quantify co-occurrence of multiple phosphorylations

Research has shown that about one-third of S845-phosphorylated subunits are also phosphorylated at T840, suggesting partial overlap between different phosphorylation sites .

Phosphomimetic Mutations:

• Generate constructs with serine-to-aspartate or serine-to-glutamate mutations at Ser849

• Examine how these mutations affect phosphorylation at other sites

• Compare with serine-to-alanine mutations that prevent phosphorylation

Mass Spectrometry for Multi-site Phosphorylation Analysis:

• Enrich for GRIA1 using immunoprecipitation

• Perform tryptic digestion

• Use mass spectrometry to identify peptides with single and multiple phosphorylation sites

• Quantify the relative abundance of each phosphorylation combination

Distinctions between sites: Research indicates different kinases target specific sites - PKA primarily phosphorylates Ser845, while CaMKII and PKC phosphorylate Ser831 . These sites also show different responses to stimuli, with Ser831 phosphorylation increased by PKC-elevating agents, while Ser845 shows higher basal phosphorylation with AKAP79 expression .

What are the methodological considerations for preventing artificial dephosphorylation of GRIA1-Ser849 during sample preparation?

Preserving the native phosphorylation state of GRIA1 at Ser849 during experimental procedures is critical for accurate analysis. Several methodological considerations should be implemented:

Phosphatase Inhibitor Cocktail Composition:

• Include multiple classes of phosphatase inhibitors:

  • Serine/threonine phosphatase inhibitors (e.g., okadaic acid, calyculin A)

  • Tyrosine phosphatase inhibitors (e.g., sodium orthovanadate)

  • Broad-spectrum inhibitors (e.g., sodium fluoride, β-glycerophosphate)

• Use freshly prepared inhibitors at appropriate concentrations

Temperature Control:

• Keep samples ice-cold throughout processing

• Minimize processing time to prevent enzymatic activity

• Consider using cooled microcentrifuges for brief spins

Buffer Optimization:

• Use buffers with optimal pH (typically 7.4) to prevent acid/base-catalyzed dephosphorylation

• Include EDTA to chelate metal ions required for phosphatase activity

• Add detergents compatible with epitope preservation

Sample Validation Controls:

• Process paired samples with and without cantharidin or other potent phosphatase inhibitors

  • Research shows cantharidin treatment significantly increases phosphorylation detection (in one study, from ~47% to ~86% for T840 phosphorylation)

• Include lambda phosphatase-treated negative controls

• Process samples in parallel with well-characterized standards

Experimental Design Controls:

• Include pharmacological treatments known to increase phosphorylation at Ser849 as positive controls

• Process all experimental conditions in parallel

• Minimize freeze-thaw cycles as they can affect phospho-epitope integrity

How can researchers differentiate between phosphorylation of GRIA1-Ser849 in homomeric GluA1 versus GluA1/GluA2 heteromeric receptors?

Distinguishing phosphorylation patterns between homomeric and heteromeric AMPA receptor configurations requires specialized approaches:

Sequential Immunoprecipitation with Subunit-Specific Antibodies :

• First immunoprecipitate with GluA2-specific antibodies to isolate heteromeric receptors

• Analyze the immunoprecipitate for phospho-Ser849 signal

• Compare with total GRIA1 immunoprecipitation

• Analyze the unbound fraction from GluA2 immunoprecipitation for remaining homomeric GluA1 receptors

Research has shown differences in phosphorylation patterns between GluA1 homomers and GluA1/GluA2 heteromers. One study found that basal GluA1 phosphorylation at Ser831 and Ser845 was elevated upon co-expression of GluA2 (Ser831: 1.29 ± 0.01, n=6; Ser845: 1.55 ± 0.13, n=6) compared to GluA1 alone .

Blue Native PAGE Combined with SDS-PAGE:

• Use native conditions to separate intact receptor complexes by size

• Follow with SDS-PAGE in the second dimension

• Blot with phospho-specific antibodies

• Different migration patterns will distinguish receptor types

Heterologous Expression Systems:

• Express tagged versions of GluA1 alone or with GluA2

• Use tag-specific antibodies to isolate distinct populations

• Quantify phospho-Ser849 levels in each population

Functional Correlation:

• Utilize electrophysiological recordings to distinguish receptor types based on current-voltage relationships and calcium permeability

• Correlate with biochemical analysis of phosphorylation status

• Use specific pharmacological agents that differentially affect homomeric versus heteromeric receptors

The interpretation should consider that AKAP79 enhances basal phosphorylation of recombinant homomeric GluA1, but doesn't significantly alter basal phosphorylation in cells expressing GluA1/GluA2 heteromers .

How do Phospho-GRIA1 (Ser849) levels correlate with synaptic plasticity phenomena such as LTP and LTD?

The correlation between Phospho-GRIA1 (Ser849) levels and synaptic plasticity is complex and involves dynamic changes in phosphorylation status:

Temporal Dynamics of Phosphorylation:

• Induction of LTP correlates with increased phosphorylation at Ser849/845

• LTD correlates with dephosphorylation at this site

• These changes can be monitored using time-course experiments with phospho-specific antibodies

Functional Significance of Phosphorylation:

• Phosphorylation at Ser849/845 potentiates AMPA receptor ion channel function by increasing channel open probability and peak current

• This site is critical for receptor trafficking and membrane localization

• Research indicates that constitutive phosphorylation by PKA at Ser845 ensures membrane localization of the subunit, while dephosphorylation following NMDA receptor activation leads to subunit internalization

Experimental Approaches to Establish Correlation:

• Electrophysiological recording combined with biochemical analysis:

  • Induce LTP or LTD in neuronal preparations

  • Fix samples at different time points

  • Quantify phosphorylation status

• Pharmacological manipulation:

  • Use PKA activators or inhibitors to modify phosphorylation

  • Measure resulting changes in synaptic strength

• Genetic models:

  • Studies using phosphomutant mice (Ser845Ala) show deficits in both LTP and LTD

  • These mice also exhibit memory deficiencies in spatial learning tasks

Research has demonstrated that under basal conditions, approximately 15-20% of GluR1 receptors are phosphorylated at Ser845, which can increase to approximately 50% under stimulated conditions (behavioral or pharmacological) .

What are the methodological considerations for using Phospho-GRIA1 (Ser849) antibodies in studies of neurological disorders?

When applying Phospho-GRIA1 (Ser849) antibodies to study neurological disorders, researchers should consider several methodological aspects:

Sample Preparation from Pathological Tissues:

• Optimize protocols for different tissue preservation methods (fresh-frozen vs. fixed)

• Consider post-mortem interval effects on phosphorylation status

• Use paired control tissue processed identically to disease samples

• Implement rapid tissue processing protocols to preserve phosphorylation states

Disease-Specific Considerations:

• Schizophrenia: GRIA1 gene (encoding GLUA1) has been identified as a putative risk gene for schizophrenia, with decreased expression in the hippocampus of schizophrenia patients

  • Consider analyzing phosphorylation in specific brain regions relevant to the disorder

• Alzheimer's Disease: Changes in AMPA receptor phosphorylation may contribute to synaptic dysfunction

  • Address potential confounding factors like protein aggregation and neuronal loss

• Ataxia: Studies have shown correlative decrease in human GRIA1 mRNA expression in cerebellum of patients with ataxia-telangiectasia and spinocerebellar ataxia type 6

  • Focus on cerebellar samples and motor circuits

Analytical Approaches:

• Quantitative Considerations:

  • Use standardized loading controls specific to neuronal samples

  • Implement phospho-to-total protein ratio analysis

  • Consider cellular heterogeneity in brain tissue samples

• Comparative Analysis Across Disorders:

  • Maintain consistent protocols when comparing multiple disorders

  • Account for disease-specific changes in total GRIA1 expression

  • Consider age, sex, and medication effects on phosphorylation

• Integration with Functional Data:

  • Correlate phosphorylation changes with electrophysiological measurements where possible

  • Consider in vivo imaging approaches to track receptor dynamics

Validation in Model Systems:

• Use genetic models like GRIA1 knockout mice to validate antibody specificity in disease contexts

• Consider iPSC-derived neurons from patients to examine phosphorylation patterns in human disease-specific cellular contexts

• Validate findings with multiple phospho-specific antibodies targeting different epitopes around the same site